Nuwellis (NASDAQ:NUWE) & CVRx (NASDAQ:CVRX) Head to Head Comparison

Nuwellis (NASDAQ:NUWE) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares Nuwellis and CVRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
CVRx	-89.14%	-120.76%	-48.38%

Earnings & Valuation

This table compares Nuwellis and CVRx”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27 million	0.05	-$17.52 million	($64.02)	0.00
CVRx	$59.07 million	2.34	-$53.31 million	($2.02)	-2.57

Nuwellis has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Nuwellis has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, CVRx has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Nuwellis and CVRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1	0	0	0	1.00
CVRx	1	0	1	2	3.00

CVRx has a consensus target price of $11.50, indicating a potential upside of 121.15%. Given CVRx’s stronger consensus rating and higher probable upside, analysts plainly believe CVRx is more favorable than Nuwellis.

Institutional and Insider Ownership

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 75.3% of CVRx shares are held by institutional investors. 1.6% of Nuwellis shares are held by company insiders. Comparatively, 13.9% of CVRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

CVRx beats Nuwellis on 13 of the 15 factors compared between the two stocks.

About Nuwellis

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.